Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/06/2024 BST 5-day change 1st Jan Change
43.09 USD +1.13% Intraday chart for Legend Biotech Corporation +3.83% -28.39%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target MT
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses MT
Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA CI
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating MT
Deutsche Bank Starts Legend Biotech With Buy Rating MT
Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA CI
MaxCyte inks deal with Legend Biotech for tech supply AN
MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program MT
Legend Expects to Log Profit in 2026 MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating MT
Legend Biotech's Loss Narrows in Q1 as Revenue Surges MT
RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Decline Pre-Bell Monday MT
Sector Update: Health Care MT
Transcript : Legend Biotech Corporation, Q1 2024 Earnings Call, May 13, 2024
Legend Biotech Q1 Net Loss Narrows as Revenue Rises; Shares Rise Pre-Bell MT
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales DJ
Stock Futures Rise Pre-Bell Ahead of Key Inflation Data; Asia, Europe Churn MT
Earnings Flash (LEGN) LEGEND BIOTECH CORPORATION Reports Q1 Revenue $94M MT
Legend Biotech Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission MT
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer MT
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma CI
Chart Legend Biotech Corporation
More charts
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
43.09 USD
Average target price
82.5 USD
Spread / Average Target
+91.47%
Consensus